This little video, combining a piece of the album Tutu , Miles Davis, and a set of graphics programs, is especially dedicated to my lovely hemato-oncologist, Dr. Normand Blais, executive
service of Hemato-Oncology Chum Notre-Dame in Montreal.
a tribute to Norman, and (Bad) memories of the research protocol
Pfizer Canada, which literally made me take out the eyes of the head.
Dr. Blais is the first doctor has me allowed in this service, it is not forgotten. Several weeks after having sent this video via email, I heard through the loudspeaker in the waiting room
service voice calling me: "Caspar Miles , cab 15, Miles Caspar . I had a three-second hesitation.
Whoever was the first to welcome me as one who will tell me the last to say:
"For treatments, it's been too much damage, you're d agree that we stop this? "
Yes, thank you, Dr. Blais
Electra - Perfect Days
Normand Blais, with Dr. Mary Florescu, followed me hang over three years. I am extremely grateful for the patience and perseverance, for all humanity, empathy, humor that have shown to me.
It to them, and treatments targeted therapies Sutent and Tarceva they offered me I must be still alive today is absolutely certain.
I feel concerned by this open letter for these reasons but also because I am one of those privileged witnesses, sick privileged few who could live and not survive
with these high-tech drugs.
Thank
Open letter to media from D Dr. Normand Blais
Following Items Patrick Lagacé ; on Cancer (La Presse), D r Normand Blais, hematologist oncologist at CHUM Hôpital Notre-Dame, has complained in an open letter media, the immobility of the Council of drugs in the acceptance of new molecules to treat cancer. Read here the full letter sent to the media ...
Many of you have recently read in the pages of this newspaper's excellent series of articles on cancer signed by Patrick Lagacé. Besides being a touching humanity, these articles have also lifted the veil on issues such as disruption of cancer care in Quebec, the inequalities of the system and the system of drug coverage. As a medical oncologist who has his practice here in Quebec, I would seize the opportunity offered by this series on cancer to highlight other taboos surrounding cancer. Lung cancer, which affects a significant number of my patients, is the deadliest form of the disease and is the leading cause of cancer death in Quebec. Paradoxically, the fact is that very little mention when talking about cancer. One of the main reasons for this state of affairs is that people associate lung cancer with the consumption of tobacco products. However, smoking is not the only element in question: the secondary or tertiary smoke, radon exposure to asbestos are all factors associated with the development of lung cancer. Moreover, it is now recognized that almost a quarter of lung cancers are smoking related, requiring a refinement in the evaluation and specific treatments. But the stigma associated with smoking contributes to people with lung cancer victims who have somehow "chosen their fate." Many support groups have a better visibility of certain types of cancers. One need only think of breast or prostate, for example. Mobilization of patients achieved and the community has helped educate a large proportion of the population to the human value of medical interventions to improve patient survival and patient suffering and improve their quality of life. The positive side of breast and prostate cancer prognosis is less severe than lung cancer, allowing many "survivors" and "survivors" to defend the rights and support of associations of patients. The harsh reality is that lung cancer makes this disease very ill with little warning period and the prognosis of the disease is severe. Very few survivors are able to participate in associations support and defend the value of new therapies specific to lung cancer.
In this regard, an example is needed: access to new drugs has become in just a few years a major issue which in turn affects the quality of care at home. In the recent past, Quebec was one of the provinces that differed in terms of access to new medicines. Since late 2005, our status is far less rosy. By considering the only cancer drug, the situation is even worse: the entity responsible for approving the reimbursement of drugs - the Council of the drug - now almost routinely refuses requests for new treatments in oncology. Unlike many other provinces in Canada where decisions on funding of drugs against cancer are taken by an agency to fight against cancer involving several members involved in the treatment of patients, no Board member has training and active practice in oncology. Clearly it is difficult to recognize the therapeutic value of a drug only prolongs survival than "few months" when the patient is not facing you. Do not forget that these drugs work very differently from one individual to another so that some patients do not benefit, but only against other patients benefit long. Articles by Lagacé showed many examples in this regard.
In my daily life, this to me raises serious ethical problems: we know there are more drugs effective and easier to tolerate for patients, but we can use them. Do we hide this fact to the patient or rather explain that another drug is more effective, but in Quebec, we can not prescribe it? While we doctors think about ethics, our patients have to fight the disease under conditions that are far from optimal. If life has a price in Quebec, let them say so openly and publicly. Otherwise, we must review the current system of access to new medicines because it no longer meets the needs of those who suffer. Also disturbing they are, it is essential to discuss these issues and discussing them publicly. The solutions are certainly not simple decisions may be heartbreaking. But this is the necessary path for improving our ways, and ultimately provide better care to Quebecers living with cancer. When treating patients with lung cancer and that they are not able to defend themselves publicly, to be their spokespersons?
Normand Blais, MD, MSc, FRCPC
hematologist and medical oncologist
Clinical Associate Professor - University of Montreal
Director, Interdisciplinary Thoracic Oncology team CHUM - Hôpital Notre-Dame
Normand Blais
Hematologist and medical oncologist, director of the interdisciplinary team of Thoracic Oncology, Laboratory Director of hemostasis-thrombosis CHUM Hospital Notre-Dame.
Hematologist and medical oncologist, director of the interdisciplinary team of Thoracic Oncology, Laboratory Director of hemostasis-thrombosis CHUM Hospital Notre-Dame.
His entry in the Faculty of Medicine is a chance of life. Normand Blais is the son of a farmer. , Almost no long studies in the family. He never felt the family pressure regarding its future. He himself never thought he had the qualifications to become specialist. "I do not intend at all to a career in medicine. I do not think being smart enough to practice this profession, I never thought of otherwise. I was passionate about science, yes, but I turned instead to a career in engineering. "After college, people crossed his path and made him understand that he had everything to succeed in medicine. On a whim, he filled out the registration form the Faculty of Medicine. "My application was accepted. A month after I started my training, I knew I belonged and that I am passionate about medicine and the human being. "
He was the doctor of Little Richard and he became friends with him. It is on a personal basis that Dr. Blais has participated in lip dub Richard Petit. It was an interesting idea, in addition to wanting to get involved with the Company Leukemia & Lymphoma Canada. On a personal level, Norman has become the challenges it makes getting involved in this company. He said yes to virtually anything that can help the hospital or the Leukemia and Lymphoma Canada.
It runs 60 kilometers a week. Currently, he trains for the New York Marathon, which takes place on November 7. In this marathon, he runs to raise money for the hospital-CHUM.
On a piece of the trio guitarist Al di Meola, Johm McLaughlin and Paco di Lucia, the slow evolution of a collage of colored tissue paper, colored and decorated with lacquer made during the research protocol of Pfizer, Sutent + pemetrexed for lung cancer nitrate . This video is also dedicated to Dr. Normand Blais, hematologist-oncologist of Chum Notre Dame in Montreal, which made me suffer a lot with cursed Sutent, which will eventually successful
Sutent + Pemetrexed
------------------------------------- -------------------------------------------------- -----------------------
André Pratte
0 comments:
Post a Comment